Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18892410 | 0.89 | NPC1 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2016946 | 0.87 | TAAR1 (0.58) | NPC1RAB9ATAAR1CNR1L3MBTL1 | |
| SCHEMBL5263204 | 0.87 | NPC1 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10242983 | 0.85 | TSHR (0.58) | KMT2ANPC1KDM4EMAPK1 | |
| SCHEMBL15466955 | 0.85 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12885093 | 0.84 | SPR (0.62) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL16294070 | 0.84 | TAAR1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8218888 | 0.83 | SMN1; SMN2 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL27087783 | 0.83 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18892533 | 0.83 | TAAR1 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2018140598-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-08-02 | — | — | WO | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| US-5350761-A | Lipoxygenase inhibitors as antiinflammatory agents and antiallergens | CIBA-GEIGY CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| US-5334600-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HDAC3 1472/4885HDAC4 2091/4885HDAC1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.